Sep 2026· European Heart Journal - Quality of Care and Clinical Outcomes· 0 citations
Medicine
TL;DR
The modified TRS-2P stratified baseline risk and provided estimates of absolute beta-blocker benefit, supporting further evaluation of individualized, risk-guided treatment after MI in patients with LVEF ≥40%.
Abstract
Aims
To assess whether a modified clinical risk-score can stratify baseline risk and estimate expected absolute benefit from beta-blocker therapy in post-MI (myocardial infarction) patients with LVEF (left ventricular ejection fraction) ≥40%.
Methods
This substudy of the BETAMI-DANBLOCK trial included patients with a recent MI and LVEF ≥40% who were randomized to beta-blocker or no beta-blocker therapy. A modified Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention (TRS-2P) was constructed, and patients were categorized as low-, intermediate-, or high-risk. The primary outcome was a composite of all-cause mortality, new-MI, unplanned coronary revascularization, ischemic stroke, heart failure, or malignant ventricular arrhythmia. Treatment effects across TRS-2P strata were estimated using Cox proportional hazards and Fine-Gray subdistribution hazard models. Three-year absolute risk reduction (ARR) and number needed to treat (NNT) were calculated for each risk stratum.
Results
Among 5558 patients, 38.4% were classified as low-risk, 52.8% as intermediate-risk, and 8.8% as high-risk. Event rates increased stepwise with higher modified TRS-2P, with no evidence of heterogeneity in the relative treatment effects across risk-strata (hazard ratios: 0.88, 0.81 and 0.88, respectively). However, the score translated the modest relative effects into clinically distinct absolute benefits: Three-year ARR was 1.4% (NNT=72 [95% CI: 41 to 361]) in low-risk, 2.1% (NNT=47 [95% CI: 27 to 239]) in intermediate-risk, and 3.6% (NNT=28 [95% CI: 16 to 140]) in high-risk patients.
Conclusions
The modified TRS-2P stratified baseline risk and provided estimates of absolute beta-blocker benefit, supporting further evaluation of individualized, risk-guided treatment after MI in patients with LVEF ≥40%.
Beta-blocker (BB) therapy after myocardial infarction (MI) in patients with reduced left ventricular ejection fraction (LVEF) is well established. However, recent randomised controlled trials (RCTs) in post-MI patients without significantly impaired LVEF have yielded conflicting results. This meta-analysis aimed...
I. F. Arba, A. Primiputri, M. B. A. Paramarta et al.· European Heart Journal, Supp...· 0 citations
In stable patients with previous myocardial infarction, left ventricular ejection fraction ≥40%, no heart failure, and no other indication for β-blocker therapy, discontinuation met the non-inferiority criteria for the primary and key secondary endpoints.
J. Silvain, Ki H. Choi, Victorien Monguillon et al.· The Lancet· 1 citation
Among patients with AMI complicated by HF, in-hospital BB use was associated with lower 1-year adverse outcomes risk in HFrEF/HFmrEF, but not in HFpEF.
In this meta-analysis of randomized clinical trials, beta-blocker use was not associated with a significant reduction in the primary composite outcome or in mortality or reinfarction, and should be interpreted with caution in the context of an overall neutral result.
L. D. Neira-Chunga, D. Moncada-Gutiérrez, G. Vásquez-Tirado et al.· Medicina Intensiva· 0 citations
OBJECTIVE
Young patients with myocardial infarction (MI) remain at risk for recurrent cardiovascular events despite favorable short-term outcomes. The prognostic significance of the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol (non-HDL-C/HDL-C) ratio in this population remains insuff...
M. Keten, Kadir Bıyıklı· Türk Kardiyoloji Derneği a...· 0 citations
A cumulative electrical risk score from the standard electrocardiogram was independently associated with appropriate ICD therapy and may add risk information beyond LVEF and warrant prospective, multicenter validation.
Muhammed Rıdvan Ersoysal, Rauf Avcı, Fatih Han Kumtaş et al.· Journal of Clinical Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.